186528-41-6

Basic information

• Product Name: (Z)-7-[(1S,2R,3R,4R)-3-(4'-Trifluoromethyl-biphenyl-4-sulfonylamino)-bicyclo[2.2.1]hept-2-yl]-hept-5-enoic acid methyl ester
• Synonyms: (Z)-7-[(1S,2R,3R,4R)-3-(4'-Trifluoromethyl-biphenyl-4-sulfonylamino)-bicyclo[2.2.1]hept-2-yl]-hept-5-enoic acid methyl ester
• CAS NO: 186528-41-6
• Molecular Weight: 535.628
• Mol File: 186528-41-6.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (Z)-7-[(1S,2R,3R,4R)-3-(4'-Trifluoromethyl-biphenyl-4-sulfonylamino)-bicyclo[2.2.1]hept-2-yl]-hept-5-enoic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (Z)-7-[(1S,2R,3R,4R)-3-(4'-Trifluoromethyl-biphenyl-4-sulfonylamino)-bicyclo[2.2.1]hept-2-yl]-hept-5-enoic acid methyl ester(186528-41-6)
• EPA Substance Registry System: (Z)-7-[(1S,2R,3R,4R)-3-(4'-Trifluoromethyl-biphenyl-4-sulfonylamino)-bicyclo[2.2.1]hept-2-yl]-hept-5-enoic acid methyl ester(186528-41-6)

Safety Data

• Hazardous Substances Data: 186528-41-6(Hazardous Substances Data)

Upstream product

• 98-61-3 p-Iodobenzenesulfonyl chloride 
• 128796-39-4 4-trifluoromethylphenylboronic acid 
• 557792-42-4 (Z)-7-[(1S,2R,3R,4R)-3-(4-Iodo-benzenesulfonylamino)-bicyclo[2.2.1]hept-2-yl]-hept-5-enoic acid methyl ester 

Relevant articles and documents

Synthesis and biological activity of various derivatives of a novel class of potent, selective, and orally active prostaglandin D2 receptor antagonists. 1. Bicyclo[2.2.1]heptane derivatives

Novel prostaglandin D2 (PGD2) receptor antagonists were synthesized as a potential new class of antiallergic agents having a bicyclo[2.2.1] heptane ring system with sulfonamide groups. Some of them exhibit extremely potent antagonism of the PGD2 receptor in radioligand binding and cAMP formation assays with IC50 values below 50 nM and much less antagonism of TXA2 and PGI2 receptors. These potent PGD2 receptor antagonists, when given orally, dramatically suppress various allergic inflammatory responses such as increased vascular permeability in allergic rhinitis, conjunctivitis, and asthma models. The excellent pharmacological profiles of PGD2 receptor antagonists, originally synthesized in our laboratories, are of potentially great clinical significance. This study also provides experimental evidence suggesting that PGD2 plays an important role in the pathogenesis of allergic diseases.